Rifaquizinone is under clinical development by TenNor Therapeutics and currently in Phase II for Liver Cirrhosis. According to GlobalData, Phase II drugs for Liver Cirrhosis does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Rifaquizinone LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Rifaquizinone is under development for the treatment of acute bacterial skin and skin structure infection, prosthetic joint infections, biofilm-associated bacterial infections, hepatic encephalopathy, cirrhosis, irritable bowel syndrome, diarrhea, hyperammonemia, and gastrointestinal tract infections including superbug and diabetic foot infections.. The drug candidate is administered through oral and intravenous route. It is a rifamycin-quinolone based hybrid antibiotic. The drug candidate is a small molecule which acts by targeting RNA polymerase, DNA gyrase and DNA topoisomerase IV. It was also under development for bacterial infections, Helicobacter pylori Infections.
TenNor Therapeutics overview
TenNor Therapeutics develops novel drugs for the treatment of infectious diseases. The company’s pipeline product portfolio includes TNP-2198 oral, TNP-2092 injection, TNP-2092 oral, TNP-2092 external preparation and others. It also carries out research and development activities for developing new drugs. The company’s TNP-2198oral uses in helicobacter pylori infection, bacterial vaginosis and clostridium infection.. TenNor Therapeutics has collaborations with 3D Bio Optima, Colorado State University, JMI Laboratories, Peking University and others. The company operates in China. TenNor Therapeutics is headquartered in Suzhou, Jiangsu, China.
For a complete picture of Rifaquizinone’s drug-specific PTSR and LoA scores, buy the report here.